Skip to main content

Table 3 Changes in biochemical parameters among the study groups

From: Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial

Parameters Linagliptin group
(n = 10)
Voglibose group
(n = 9)
Control group
(n = 7)
P-Value Linagliptin V/S Control P-Value Voglibose V/S Control P-Value Voglibose V/S Linagliptin
∆HbA1c (%) −0.2(− 0.6 to 0.3) −0.8(− 0.9 to − 0.1) 0.1(− 0.1 to 0.3) 0.422 0.038a 0.723
Mixed Meal Tolerance Test
 ∆AUC C-pep (nmol/L) −100.5 (− 174.8 to 75.6) − 80.3 (− 217.6 to 15.0) −24.9 (− 153.2184.6) 0.669 0.470 0.780
 ∆M0 × 10− 8 (1/min) 1.5(0.2 to 2.7) 3.5(− 1.4 to 3.9) 3.7(0.6 to 6.7) 0.497 0.918 0.475
 ∆M1 ×10−8 (1/min) −2.1(−3.7 to 0.2) −3.3(−6.4 to 2.1) −3.8(− 6.1 to 0.6) 0.842 1.000 0.536
Hyperinsulinemic-Euglycemic Clamp Study
 ∆Glucose disposal rate (mg/Kg min) 0.5(−0.2 to 0.7) 0.2(0.1 to 0.5) 0.1(−0.4 to 0.4) 0.536 0.470 0.842
 ∆Insulin sensitivity (mg/(Kgmin)/μU/mL) 0.6(−1.5 to 1.3) 0.2(−0.9 to 0.9) 0.2(−0.8 to 0.7) 0.601 0.905 0.837
  1. All values are expressed as median and interquartile range (1st IQR to 3rd IQR). −Decrease from baseline. aSignificant difference within the group
  2. AUC Area under curve, M0 Basal β-cell function, M1 postprandial β-cell function